Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gilead Files JAK Inhibitor Filgotinib in Japan
Gilead Sciences said on October 8 that it has filed a new drug application in Japan for its oral JAK1 inhibitor filgotinib for the treatment of adults with rheumatoid arthritis (RA).The submission is based on data from a PIII global…
To read the full story
Related Article
- Gilead Japan Hooks Up with Arthritis-Savvy Eisai for JAK Inhibitor
December 25, 2019
BUSINESS
- Meiji Pharma Asia Launches Operations in Singapore
April 9, 2026
- Shionogi Signs US Government Contract to Boost Cefiderocol Supply
April 9, 2026
- Sumitomo Pharma to Raise up to 116.5 Billion Yen for R&D, Debt Reduction
April 9, 2026
- Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
- BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…